DARA BioSciences, Inc., a specialty pharmaceutical company, focuses on commercialization of oncology treatment and supportive care pharmaceutical products in the United States. The company s products comprise Soltamox, an oral solution for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups; Gelclair, an oral gel for the treatment of oral mucositis; Bionect for the management of irritation of the skin, as well as first and second degree burns; Ferralet 90 for treatment of anemia; and Aquoral for treatment of cancer. Its clinical development products include KRN5500, a novel, non-narcotic/non-opioid intravenous product for the treatment of cancer patients with painful chronic chemotherapy induced peripheral neuropathy, which has completed Phase 2a development. The company was incorporated in 2002 and is headquartered in Raleigh, North Carolina. As of December 7, 2015, DARA BioSciences, Inc operates as a subsidiary of Midatech Pharma Plc.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for DARA